Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer

被引:0
作者
Yang, Shi-Ping [1 ]
Liu, Ke [2 ]
Li, Yang [3 ]
Li, Guan-Qiao [4 ]
Li, Jia-Yi [5 ]
Lin, Yu-Yi [6 ,8 ]
Wu, San-Gang [7 ]
机构
[1] Hainan Med Univ, Hainan Gen Hosp, Dept Radiat Oncol, Hainan Affiliated Hosp, Haikou, Peoples R China
[2] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Tradit Chinese Med, Xiamen, Peoples R China
[3] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Peoples R China
[4] Hainan Med Univ, Hainan Gen Hosp, Dept Breast Surg, Hainan Affiliated Hosp, Haikou, Peoples R China
[5] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Sch Med, Xiamen, Peoples R China
[6] Xiamen Med Coll, Dept Radiat Oncol, Affiliated Hosp 2, Xiamen, Peoples R China
[7] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Sch Med, Xiamen, Peoples R China
[8] Xiamen Med Coll, Dept Radiat Oncol, Affiliated Hosp 2, Xiamen 361021, Peoples R China
关键词
Breast cancer; metastatic stage; Oncotype; prognosis; chemotherapy; POSITIVE NODES; PALBOCICLIB; LETROZOLE; THERAPY; IMPACT; ASSAY;
D O I
10.1080/14737159.2024.2301940
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Limited data exist regarding the utility and validity of the 21-gene recurrence score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to investigate the practice patterns as well as associated survival outcomes based on 21-gene RS in dnMBC.Research design and methods: The Surveillance, Epidemiology, and End Results Oncotype database was queried for women with hormone receptor-positive and Her2-negative dnMBC.Results: A total of 153 patients were identified, including 62.7% and 37.3% of patients who had RS < 26 and >= 26, respectively. Patients with RS >= 26 were more likely to receive chemotherapy compared to those with RS < 26 (61.4% vs. 28.1%, p < 0.001). Patients with RS >= 26 had an inferior breast cancer-specific survival (BCSS) (2-year BCSS: 84.3% vs. 89.5, p = 0.067) and overall survival (OS) compared to those with RS < 26 (2-year OS: 76.9% vs. 87.4%, p = 0.018). The multivariate Cox proportional hazard models showed that those with RS >= 26 had a significantly inferior BCSS (hazard ratio [HR] 2.251, 95% confidence interval [CI] 1.056-4.799, p = 0.036) and OS (HR 2.151, 95%CI 1.123-4.120, p = 0.021) compared to those with RS < 26.Conclusions: The 21-gene RS assay is an important prognostic factor in patients with dnMBC.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 35 条
[1]   The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer [J].
Ahmed, Shahid ;
Pati, Sukanya ;
Le, Duc ;
Haider, Kamal ;
Iqbal, Nayyar .
JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (02) :144-154
[2]   Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients [J].
Amro, Ali ;
Chen, Yalei ;
Barry, Renee ;
Susick, Laura ;
Bensenhaver, Jessica ;
Proctor, Erica ;
Petersen, Lindsay ;
Nathanson, S. David ;
Ali, Haythem ;
Loutfi, Randa ;
Chitale, Dhananjay ;
Simonds, Alyson ;
Kuklinski, Marcia ;
Park, Ko Un ;
Davis, Melissa ;
Newman, Lisa A. .
BREAST JOURNAL, 2019, 25 (04) :667-671
[3]   Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J].
Badwe, Rajendra ;
Hawaldar, Rohini ;
Nair, Nita ;
Kaushik, Rucha ;
Parmar, Vani ;
Siddique, Shabina ;
Budrukkar, Ashwini ;
Mittra, Indraneel ;
Gupta, Sudeep .
LANCET ONCOLOGY, 2015, 16 (13) :1380-1388
[4]   Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer [J].
Beddok, Arnaud ;
Mouren, Victoire ;
Cottu, Paul ;
Laki, Fatima ;
Fourquet, Alain ;
Kirova, Youlia .
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (07) :1386-1396
[5]   Does the 21-gene recurrence score have clinical utility in HR+/HER2+breast cancer? [J].
Bilani, Nadeem ;
Crowley, Fionnuala ;
Mohanna, Mohamed ;
Itani, Mira ;
Yaghi, Marita ;
Saravia, Diana ;
Jabbal, Iktej ;
Dominguez, Barbara ;
Liang, Hong ;
Nahleh, Zeina .
BREAST, 2022, 66 :49-53
[6]   5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].
Cardoso, F. ;
Paluch-Shimon, S. ;
Senkus, E. ;
Curigliano, G. ;
Aapro, M. S. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Bhattacharyya, G. S. ;
Biganzoli, L. ;
Boyle, F. ;
Cardoso, M-J ;
Carey, L. A. ;
Cortes, J. ;
El Saghir, N. S. ;
Elzayat, M. ;
Eniu, A. ;
Fallowfield, L. ;
Francis, P. A. ;
Gelmon, K. ;
Gligorov, J. ;
Haidinger, R. ;
Harbeck, N. ;
Hu, X. ;
Kaufman, B. ;
Kaur, R. ;
Kiely, B. E. ;
Kim, S-B ;
Lin, N. U. ;
Mertz, S. A. ;
Neciosup, S. ;
Offersen, B., V ;
Ohno, S. ;
Pagani, O. ;
Prat, A. ;
Penault-Llorca, F. ;
Rugo, H. S. ;
Sledge, G. W. ;
Thomssen, C. ;
Vorobiof, D. A. ;
Wiseman, T. ;
Xu, B. ;
Norton, L. ;
Costa, A. ;
Winer, E. P. .
ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649
[7]   Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].
Cristofanilli, Massimo ;
Turner, Nicholas C. ;
Bondarenko, Igor ;
Ro, Jungsil ;
Im, Seock-Ah ;
Masuda, Norikazu ;
Colleoni, Marco ;
DeMichele, Angela ;
Loi, Sherene ;
Verma, Sunil ;
Iwata, Hiroji ;
Harbeck, Nadia ;
Zhang, Ke ;
Theall, Kathy Puyana ;
Jiang, Yuqiu ;
Bartlett, Cynthia Huang ;
Koehler, Maria ;
Slamon, Dennis .
LANCET ONCOLOGY, 2016, 17 (04) :425-439
[8]   Palbociclib and Letrozole in Advanced Breast Cancer [J].
Finn, Richard S. ;
Martin, Miguel ;
Rugo, Hope S. ;
Jones, Stephen ;
Im, Seock-Ah ;
Gelmon, Karen ;
Harbeck, Nadia ;
Lipatov, Oleg N. ;
Walshe, Janice M. ;
Moulder, Stacy ;
Gauthier, Eric ;
Lu, Dongrui R. ;
Randolph, Sophia ;
Dieras, Veronique ;
Slamon, Dennis J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936
[9]   The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].
Finn, Richard S. ;
Crown, John P. ;
Lang, Istvan ;
Boer, Katalin ;
Bondarenko, Igor M. ;
Kulyk, Sergey O. ;
Ettl, Johannes ;
Patel, Ravindranath ;
Pinter, Tamas ;
Schmidt, Marcus ;
Shparyk, Yaroslav ;
Thummala, Anu R. ;
Voytko, Nataliya L. ;
Fowst, Camilla ;
Huang, Xin ;
Kim, Sindy T. ;
Randolph, Sophia ;
Slamon, Dennis J. .
LANCET ONCOLOGY, 2015, 16 (01) :25-35
[10]   Incorporation of biologic factors for the staging of de novo stage IV breast cancer [J].
He, Zhen-Yu ;
Lian, Chen-Lu ;
Wang, Jun ;
Lei, Jian ;
Hua, Li ;
Zhou, Juan ;
Wu, San-Gang .
NPJ BREAST CANCER, 2020, 6 (01)